Alkermes plc (ALKS)
Chart Events
Performance Outlook
| Previous Close | 22.00 |
| Open | 21.90 |
| Bid | 22.20 x 900 |
| Ask | 22.40 x 1400 |
| Day's Range | 21.46 - 22.46 |
| 52 Week Range | 11.98 - 22.55 |
| Volume | 2,026,381 |
| Avg. Volume | 1,261,141 |
| Market Cap | 3.56B |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.46 |
| Earnings Date | Feb 10, 2021 - Feb 15, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.18 |
- Zacks
Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status
Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.
- Zacks
Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study
Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.
- PR Newswire
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
Results from a National Institute on Drug Abuse (NIDA)-funded study evaluating the efficacy and safety of naltrexone for extended-release injectable suspension (XR-NTX) administered once every three weeks plus oral extended-release bupropion administered daily as a combination treatment for adults with moderate or severe methamphetamine use disorder (MUD) were published today by Dr. Madhukar H. Trivedi et al. in the New England Journal of Medicine (NEJM).1 This is the second published study evaluating this combination regimen for the treatment of MUD.2
